103 related articles for article (PubMed ID: 38729824)
1. Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours.
Dieckmann KP; Grobelny F; Soave A; Che Y; Nestler T; Matthies C; Heinzelbecker J; Winter A; Heidenreich A; Niemzok T; Dumlupinar C; Angerer M; Wülfing C; Paffenholz P; Belge G
Eur Urol Focus; 2024 May; ():. PubMed ID: 38729824
[TBL] [Abstract][Full Text] [Related]
2. Serum Levels of MicroRNA-371a-3p (M371) Can Predict Absence or Presence of Vital Disease in Residual Masses After Chemotherapy of Metastatic Seminoma.
Dieckmann KP; Klemke M; Grobelny F; Radtke A; Dralle-Filiz I; Wülfing C; Belge G
Front Oncol; 2022; 12():889624. PubMed ID: 35600346
[TBL] [Abstract][Full Text] [Related]
3. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
4. Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1.
Dieckmann KP; Dumlupinar C; Radtke A; Matthies C; Pichler R; Paffenholz P; Sommer J; Winter A; Zengerling F; Hennig F; Wülfing C; Belge G
World J Urol; 2022 Feb; 40(2):317-326. PubMed ID: 34775512
[TBL] [Abstract][Full Text] [Related]
5. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
[TBL] [Abstract][Full Text] [Related]
6. Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.
Belge G; Dumlupinar C; Nestler T; Klemke M; Törzsök P; Trenti E; Pichler R; Loidl W; Che Y; Hiester A; Matthies C; Pichler M; Paffenholz P; Kluth L; Wenzel M; Sommer J; Heinzelbecker J; Schriefer P; Winter A; Zengerling F; Kramer MW; Lengert M; Frey J; Heidenreich A; Wülfing C; Radtke A; Dieckmann KP
Clin Cancer Res; 2024 Jan; 30(2):404-412. PubMed ID: 37967143
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
[TBL] [Abstract][Full Text] [Related]
8. High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours.
Dieckmann KP; Hennig F; Anheuser P; Gehrckens R; Viehweger F; Wülfing C; Belge G
Urol Int; 2021; 105(1-2):21-26. PubMed ID: 33049748
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin.
Belge G; Grobelny F; Radtke A; Bodes J; Matthies C; Wülfing C; Dieckmann KP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):435-443. PubMed ID: 33200255
[TBL] [Abstract][Full Text] [Related]
10. Testicular neoplasms: the interrelationships of serum levels of microRNA-371a-3p (M371) and classical tumor markers with histology, clinical staging, and age-a statistical analysis.
Dieckmann KP; Dumlupinar C; Grobelny F; Utschig J; Klemke M; Ahmed Saad EM; Wülfing C; Pichlmeier U; Isbarn H; Belge G
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7079-7090. PubMed ID: 36869885
[TBL] [Abstract][Full Text] [Related]
11. The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens.
Kremer L; von Brandenstein M; Wittersheim M; Koeditz B; Paffenholz P; Hellmich M; Pfister D; Heidenreich A; Nestler T
Transl Androl Urol; 2021 Apr; 10(4):1647-1655. PubMed ID: 33968653
[TBL] [Abstract][Full Text] [Related]
12. Circulating MicroRNAs for Detection of Germ Cell Tumours: A Narrative Review.
Fankhauser CD; Nuño MM; Murray MJ; Frazier L; Bagrodia A
Eur Urol Focus; 2022 May; 8(3):660-662. PubMed ID: 35537936
[TBL] [Abstract][Full Text] [Related]
13. Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review.
Leão R; Albersen M; Looijenga LHJ; Tandstad T; Kollmannsberger C; Murray MJ; Culine S; Coleman N; Belge G; Hamilton RJ; Dieckmann KP
Eur Urol; 2021 Oct; 80(4):456-466. PubMed ID: 34175151
[TBL] [Abstract][Full Text] [Related]
14. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
16. The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.
Radtke A; Hennig F; Ikogho R; Hammel J; Anheuser P; Wülfing C; Belge G; Dieckmann KP
Urol Int; 2018; 100(4):470-475. PubMed ID: 29698973
[TBL] [Abstract][Full Text] [Related]
17. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
18. Testicular Neoplasms: Primary Tumour Size Is Closely Interrelated with Histology, Clinical Staging, and Tumour Marker Expression Rates-A Comprehensive Statistical Analysis.
Dieckmann KP; Isbarn H; Grobelny F; Dumlupinar C; Utschig J; Wülfing C; Pichlmeier U; Belge G
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358866
[TBL] [Abstract][Full Text] [Related]
19. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
[TBL] [Abstract][Full Text] [Related]
20. Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor.
Belge G; Hennig F; Dumlupinar C; Grobelny F; Junker K; Radtke A; Dieckmann KP
Oncotarget; 2020 Apr; 11(16):1462-1473. PubMed ID: 32363003
[No Abstract] [Full Text] [Related]
[Next] [New Search]
